Screener
Celldex Therapeutics CLDX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's retained earnings?
- Celldex Therapeutics (CLDX) reported retained earnings of -$1.97B in Q2 2026.
- How has Celldex Therapeutics's retained earnings changed year-over-year?
- Celldex Therapeutics's retained earnings decreased by 18.0% year-over-year, from -$1.67B to -$1.97B.
- What is the long-term trend for Celldex Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Celldex Therapeutics's retained earnings has grown at a 11.1% compound annual growth rate (CAGR), from -$1.07B to -$1.81B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Celldex Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude